CTLA4 and neoplasm: In addition to its anti-angiogenic properties, sunitinib treatment reduces the number of immunosuppressive MDSCs and regulatory T-cells (Tregs) in the tumor and decreases expression of CTLA-4 and PD-1 on tumor infiltrating T-cells [17].